Metavia Inc (MTVA) Stock Price, Quote & News

Company Profile

MetaVia Inc., a clinical-stage biotechnology company, focuses on developing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, as well as completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus; and DA-1726, a novel oxyntomod...

Industry: Biotechnology

Sector: Healthcare

Phone: 857 702 9600

Website: www.metaviatx.com

Address:

545 Concord Avenue, Suite 210, Cambridge, United States

Grimalkins_star Nov. 14 at 3:59 PM

$MTVA won’t be this low for long. Get on the train or get left in the station folks 🚂📈☘️

0 · Reply

Vutch Nov. 14 at 3:35 PM

$MTVA Dong-A ST is a parent company that owns majority shares of MetaVia and they are trying to enter the US market. In case you don't know what a parent company is, it's a business that controls or owns a majority of another company, known as a subsidiary. It's no different than Toyota Motor Corporation(parent company) owning Toyota Motor North America(subsidiary). So with that being said, both companies are developing DA-1241 and DA-1726 together to cover the US market. If one suffers or wins, so is the other and vice versa. DA-1726 48 mg MAD data to be announced very soon!

0 · Reply

Kertzi Nov. 14 at 5:43 AM

$MTVA Do you understand how terrible this scam is? Dong-ST had MetaVia develop drug candidates, but Dong-ST owns the global intellectual property rights. Yes, the MetaVia license only covers the US market. Dong is diluting MetaVia shareholder value by developing its own assets! Dong can and will pull the plug at any time. And there's more: This is also heading to OTC! EXTREMELY BEARISH!

0 · Reply

Kertzi Nov. 13 at 4:49 PM

$MTVA

0 · Reply

Zackpedia Nov. 13 at 4:44 PM

$MTVA You could’ve sold when I alerted and bought back at .6 now if you wanted.

0 · Reply

Kertzi Nov. 12 at 2:29 PM

$MTVA ATH 130.000$/share = NeuroScam, Korea

1 · Reply

Ren_Stimpy Nov. 12 at 11:48 AM

$MTVA Government shutdown! Not sure what factor this might play. Not sure if the SEC was affected by the government shutdown. Interested to see how this all plays out.

0 · Reply

SPYmyQQQ Nov. 12 at 11:03 AM

🚀 New Signal ✅ 💊 $MTVA 🗓️ Nov 12, 2025 💵 Entry: $0.7400 🎯 Target (Opt.): $0.8756 (+18.32%) 👉 FREE TRIAL! spymyqqq/join/

1 · Reply

sandymartin Nov. 12 at 2:29 AM

$MTVA $MSTR The bulls have single-handedly reversed the market structure. https://stocktwits.com/sandymartin

0 · Reply

warrants_Moon Nov. 11 at 11:35 PM

$MTVA dilution here won’t matter. Has a pipeline equivalent to $MTSR meta via should be on the radar, for everyone. This won’t be this low for long

0 · Reply

MetaVia Presents Positive New Phase 2a Data on Vanoglipel (DA-1241) in Patients with Presumed MASH at the AASLD The Liver Meeting® 2025

Nov 6, 2025, 8:31 AM EST - 8 days ago

MetaVia Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 4, 2025, 4:01 PM EST - 10 days ago

MetaVia to Present New Phase 1 and Pre-Clinical Data on DA-1726 at ObesityWeek® 2025

Oct 27, 2025, 8:31 AM EDT - 18 days ago

MetaVia Announces Poster Presentation on Vanoglipel (DA-1241) at the AASLD Liver Meeting

Oct 20, 2025, 8:31 AM EDT - 25 days ago

MetaVia Announces Poster Presentations on DA-1726 at ObesityWeek® 2025

Oct 14, 2025, 8:31 AM EDT - 4 weeks ago

MetaVia to Present at the H.C. Wainwright Liver Disease Virtual Conference

Aug 26, 2025, 8:31 AM EDT - 2 months ago

MetaVia to Present at Upcoming Investor and Industry Conferences

Aug 7, 2025, 8:31 AM EDT - 3 months ago

MetaVia Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 6, 2025, 8:31 AM EDT - 3 months ago

MetaVia Extends 48 mg MAD Portion of Its Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity to 8 Weeks and Announces Fifth Weekly Dose in First Patient

Aug 4, 2025, 8:31 AM EDT - 3 months ago

MetaVia Announces AI-Driven Collaboration with Syntekabio to Explore Additional Indications for DA-1241

Jul 9, 2025, 8:31 AM EDT - 4 months ago

MetaVia Doses First Patient in the 48 mg MAD Cohort of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity to Further Explore Maximum Tolerated Dose

Jun 21, 2025, 9:00 AM EDT - 5 months ago

MetaVia Presents Pre-Clinical Data on DA-1241 Demonstrating Additive Hepatoprotective Effects in Combination With Efruxifermin at the ADA's 85th Scientific Session

Jun 10, 2025, 8:31 AM EDT - 5 months ago

MetaVia to Present at the Life Sciences Virtual Investor Forum June 12th

Jun 4, 2025, 8:31 AM EDT - 5 months ago

MetaVia Announces Poster Presentation on DA-1241 at the ADA's 85th Scientific Sessions

May 14, 2025, 4:05 PM EDT - 6 months ago

MetaVia Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 9, 2025, 8:01 AM EDT - 6 months ago

MetaVia Announces $10.0 Million Private Placement Priced At-The-Market under Nasdaq Rules

May 7, 2025, 2:00 AM EDT - 6 months ago

MetaVia Presents Data on DA-1241, a GPR119 Agonist, Demonstrating Both Hepatoprotective and Glucose-Regulating Effects in Patients with Presumed MASH, at the EASL Congress 2025

Apr 23, 2025, 8:31 AM EDT - 7 months ago

MetaVia Announces Late-Breaking Poster Presentation on DA-1241 at the EASL Congress 2025

Apr 22, 2025, 8:31 AM EDT - 7 months ago

MetaVia Reports Additional Positive Top-Line Results From the MAD Part 2 of Its Phase 1 Study of DA-1726, a Novel 3:1 Ratio GLP-1 and Glucagon Dual Receptor Agonist to Treat Obesity, Further Demonstrating Its Best-In-Class Potential

Apr 15, 2025, 7:01 AM EDT - 7 months ago

MetaVia Announces Positive Top-Line Data From the 4-Week Phase 1 MAD Trial of DA-1726, a Novel 3:1 Ratio GLP-1 Glucagon Dual Receptor Agonist to Treat Obesity, Showing Compelling Weight Loss and Safety Effects With Potential Best-In-Class Glucose Control (GLP-1R), Waist Reduction (GCGR), and Tolerability

Mar 20, 2025, 7:31 AM EDT - 8 months ago

MetaVia Reports Year End 2024 Financial Results and Provides Corporate Update

Jan 10, 2025, 8:05 AM EST - 11 months ago

MetaVia to Hold Advisory Committee Meeting at the 9th Annual MASH-TAG 2025 Conference

Nov 18, 2024, 8:01 AM EST - 1 year ago

NeuroBo Pharmaceuticals Announces Strategic Realignment Ahead of Important Clinical Milestones with Name Change to MetaVia - Reflecting the Company's Focus on Cardiometabolic Diseases

Nov 13, 2024, 8:01 AM EST - 1 year ago

NeuroBo Pharmaceuticals to Participate in Investor Conferences in November

Nov 7, 2024, 8:01 AM EST - 1 year ago

NeuroBo Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 4, 2024, 8:01 AM EST - 1 year ago

NeuroBo Pharmaceuticals Completes Last Patient Last Visit in Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH

Oct 1, 2024, 8:01 AM EDT - 1 year ago

NeuroBo Pharmaceuticals to Participate in Investor Conferences in October

Sep 30, 2024, 8:01 AM EDT - 1 year ago

NeuroBo Pharmaceuticals Announces Positive Top-Line Data From the SAD Part 1 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

Sep 3, 2024, 8:01 AM EDT - 1 year ago

NeuroBo to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Aug 14, 2024, 8:01 AM EDT - 1 year ago

NeuroBo Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 13, 2024, 8:01 AM EDT - 1 year ago

NeuroBo Pharmaceuticals Completes Enrollment of the SAD Part 1 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

Aug 6, 2024, 8:01 AM EDT - 1 year ago

NeuroBo Pharmaceuticals Announces Joint Research Agreement, Together with Dong-A ST and ImmunoForge to Develop a Long-Acting Once-Monthly Formulation of DA-1726 for the Treatment of Obesity

Jul 30, 2024, 8:01 AM EDT - 1 year ago

NeuroBo Pharmaceuticals Announces Exclusive License Agreement with MThera Pharma for NB-01

Jul 11, 2024, 8:01 AM EDT - 1 year ago

NeuroBo Pharmaceuticals to Present at the Emerging Growth Conference in July

Jun 26, 2024, 9:06 AM EDT - 1 year ago

NeuroBo Pharmaceuticals Doses First Patient in the MAD Part 2 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

Jun 25, 2024, 5:08 PM EDT - 1 year ago

NeuroBo Pharmaceuticals Announces the Closing of up to $70 Million Concurrent Private Placement and Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jun 24, 2024, 8:01 AM EDT - 1 year ago

NeuroBo Pharmaceuticals Announces up to $70 Million Concurrent Private Placement and Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jun 22, 2024, 8:01 AM EDT - 1 year ago

NeuroBo Pharmaceuticals' DA-1726 Demonstrated Superiority in Weight Loss, Retention of Lean Body Mass, and Lipid-Lowering Effects Compared to Survodutide, in Pre-Clinical Models

May 22, 2024, 8:01 AM EDT - 1 year ago

NeuroBo Pharmaceuticals' DA-1241 in Combination with Semaglutide Improves Liver Fibrosis and Demonstrates Additive Hepatoprotective Effects in Pre-Clinical MASH Models Compared to Either Treatment, Alone

May 9, 2024, 8:01 AM EDT - 1 year ago

NeuroBo Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update

Apr 30, 2024, 8:01 AM EDT - 1 year ago

NeuroBo to Present Latest Pre-Clinical Data on Cardiometabolic Assets, DA-1241 and DA-1726, Targeting MASH and Obesity, at Scientific Conferences in June

Apr 17, 2024, 8:05 AM EDT - 1 year ago

NeuroBo Pharmaceuticals Doses First Patient in Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

Apr 1, 2024, 8:01 AM EDT - 1 year ago

NeuroBo Pharmaceuticals Completes Enrollment of Part 1 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH

Mar 28, 2024, 8:01 AM EDT - 1 year ago

NeuroBo Pharmaceuticals Reports Year End 2023 Financial Results and Provides Corporate Update

Mar 13, 2024, 8:01 AM EDT - 1 year ago

NeuroBo Pharmaceuticals Receives Safety Review Committee Approval to Continue With Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH

Mar 4, 2024, 8:01 AM EST - 1 year ago

NeuroBo Pharmaceuticals Appoints Seasoned Life Science Executive Marshall Woodworth as Chief Financial Officer

Feb 29, 2024, 8:01 AM EST - 1 year ago

NeuroBo Pharmaceuticals Receives First Site IRB Approval for Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

Feb 12, 2024, 8:01 AM EST - 1 year ago

NeuroBo Pharmaceuticals to Participate in the BIO CEO & Investor Conference

Feb 1, 2024, 8:01 AM EST - 1 year ago

NeuroBo Pharmaceuticals Announces FDA Clearance of IND for a Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity

Jan 18, 2024, 8:01 AM EST - 1 year ago

NeuroBo Pharmaceuticals Reports Positive Pre-Clinical Safety Data of DA-1241 in Combination with Sitagliptin and Opens Enrollment for Part 2 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH

Grimalkins_star Nov. 14 at 3:59 PM

$MTVA won’t be this low for long. Get on the train or get left in the station folks 🚂📈☘️

0 · Reply

Vutch Nov. 14 at 3:35 PM

0 · Reply

Kertzi Nov. 14 at 5:43 AM

0 · Reply

Kertzi Nov. 13 at 4:49 PM

$MTVA

0 · Reply

Zackpedia Nov. 13 at 4:44 PM

$MTVA You could’ve sold when I alerted and bought back at .6 now if you wanted.

0 · Reply

Kertzi Nov. 12 at 2:29 PM

$MTVA ATH 130.000$/share = NeuroScam, Korea

1 · Reply

Ren_Stimpy Nov. 12 at 11:48 AM

$MTVA Government shutdown! Not sure what factor this might play. Not sure if the SEC was affected by the government shutdown. Interested to see how this all plays out.

0 · Reply

SPYmyQQQ Nov. 12 at 11:03 AM

🚀 New Signal ✅ 💊 $MTVA 🗓️ Nov 12, 2025 💵 Entry: $0.7400 🎯 Target (Opt.): $0.8756 (+18.32%) 👉 FREE TRIAL! spymyqqq/join/

1 · Reply

sandymartin Nov. 12 at 2:29 AM

$MTVA $MSTR The bulls have single-handedly reversed the market structure. https://stocktwits.com/sandymartin

0 · Reply

warrants_Moon Nov. 11 at 11:35 PM

$MTVA dilution here won’t matter. Has a pipeline equivalent to $MTSR meta via should be on the radar, for everyone. This won’t be this low for long

0 · Reply

Zackpedia Nov. 11 at 1:28 PM

$MTVA Buy back around .7 now if you want

1 · Reply

Ren_Stimpy Nov. 11 at 1:05 PM

Warning! Don’t trade $MTVA unless we’re a gabbling man!! They have to close above $1 by tomorrow to stay listed on the Nasdaq. This could go three ways. 1) they get delisted from Nasdaq 2) they reverse split stock which needs to be announced after closing today. 3) they get a extension from the Nasdaq

0 · Reply

Ren_Stimpy Nov. 11 at 12:29 PM

$MTVA In accordance with Nasdaq Marketplace Rule 5810(c)(3)(A), the Company has a period of 180 calendar days from May 29, 2025, or until November 25, 2025, to regain compliance with the Minimum Bid Price Requirement. If at any time before November 25, 2025, the closing bid price of the Company’s common stock closes at or above $1.00 per share for a minimum of 10 consecutive business days https://www.sec.gov/ix?doc=/Archives/edgar/data/1638287/000110465925054976/tm2516553d1_8k.htm

0 · Reply

BioRich Nov. 11 at 3:32 AM

$MTVA Loaded again. Nice opportunity this low. Looking forward to corporate/trial updates. This has proven to get a great one to hold a core position (hold long) and varying levels of swing trade shares. This one has been pretty frustrating, if you let it. Play the stock, don't let the stock play you. Follow/Subscribe for more suggestions and perspective. Would love to hear yours too. That's how we find these gems and learn. Let's make some money. Cheers!

2 · Reply

bjhbj Nov. 10 at 10:30 PM

$MTVA

0 · Reply

SMARTR8 Nov. 10 at 9:13 PM

$MTVA keep it going!! 🎯

0 · Reply

ZacksSCR Nov. 10 at 7:25 PM

$MTVA: 8-Week Data for 48 mg Cohort in Phase 1 Obesity Study Expected Before End of 2025… https://buff.ly/AfB8NVp

0 · Reply

Ren_Stimpy Nov. 10 at 6:00 PM

$MTVA sold my shares at a loss because I believe there’s insider trading. I believe reverse split imminent.. just my opinion.. read sec filing https://www.sec.gov/ix?doc=/Archives/edgar/data/0001638287/000155837025009000/mtva-20250630x8k.htm

1 · Reply

redcandlelover Nov. 10 at 5:26 PM

$MTVA added here. seems to be bottoming out

0 · Reply

warrants_Moon Nov. 10 at 5:11 PM

$MTVA time to slap

0 · Reply

SMARTR8 Nov. 10 at 5:04 PM

$MTVA this should no be trading this low. There is a lot of potential here. That's it for now 🤫

0 · Reply

Grimalkins_star Nov. 10 at 2:48 PM

$MTVA time to get on the train 🚂 ⬆️

0 · Reply

Market Cap	17.11M
Revenue (ttm)	0.00
Net Income (ttm)	-27.59M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	193,194
Avg Vol	3,428,634
Day's Range	N/A - N/A
Shares Out	24.22M
Stochastic %K	4%
Beta	0.37
Analysts	Strong Sell
Price Target	$14.25